Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
OptimizeRx Corp.
OPRX
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $114.1M
$6.19
▲ +1.81%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$4.54 - $22.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 53.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Embedded EMR and eRx integration creating high switching costs and recurring revenue
- HIPAA-compliant cloud infrastructure with direct patient engagement capabilities
- Real-world data analytics enabling precision physician targeting and patient identification
- Multi-stakeholder network effects across pharma manufacturers, providers, and patients
- Proprietary drug file integration and sales force enablement expertise
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Increasing pharmaceutical industry adoption of digital patient engagement and eRx solutions
Value
Deep value opportunity - significant discount to Healthcare IT & Services peers
Momentum
Weak
-7.3% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying OPRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 12, 2026
Reported EPS of $0.14 vs $0.01 consensus (+1300.0% surprise). Revenue of $19.8M vs $18.4M expected (+8.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+1300.0%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
+14%
+11%
+55%
+22%
-0%
-10%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$18.8M
$21.3M
$32.3M
$21.9M
$29.2M
$26.1M
$32.2M
$19.8M
Margins · last 8Q
Gross
—
Operating
—
Profit
-2.5%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
$10.50
▲ +69.6% vs $6.19
Latest: Stephens · $7.00 · May 13, 2026
4 analysts covering